Thromb Haemost 2002; 87(05): 925-926
DOI: 10.1055/s-0037-1613110
Letters to the Editor
Schattauer GmbH

Pulmonary Embolism After Sequential Use of Recombinant Factor VIIa and Activated Prothrombin Complex Concentrate in a Factor VIII Inhibitor Patient

Stephan B. Rosenfeld
1   Department of Internal Medicine, University of Iowa College of Medicine, Iowa City, IA
,
Karla K. Watkinson
2   Department of Great Plains Regional Hemophilia Treatment Center, Iowa City, IA
,
Brad H. Thompson
3   Department of Radiology, University of Iowa College of Medicine, Iowa City, IA
,
Donald E. Macfarlane
1   Department of Internal Medicine, University of Iowa College of Medicine, Iowa City, IA
2   Department of Great Plains Regional Hemophilia Treatment Center, Iowa City, IA
,
Steven R. Lentz
1   Department of Internal Medicine, University of Iowa College of Medicine, Iowa City, IA
2   Department of Great Plains Regional Hemophilia Treatment Center, Iowa City, IA
4   Department of Veterans Affairs Medical Center, Iowa City, IA, USA
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Received 25. Januar 2002

Accepted 30. Januar 2002

Publikationsdatum:
11. Dezember 2017 (online)

 

 
  • References

  • 1 Kessler CM. New products for managing inhibitors to coagulation factors: a focus on recombinant factor VIIa concentrate. Curr Opin Hematol 2000; 07: 408-13.
  • 2 Ewenstein BM. Continuous infusion of recombinant factor VIIa: continue or not?. Thromb Haemost 2001; 86: 942-4.
  • 3 Aledort LM. Adverse reactions related to rVIIa?. Am J Hematol 2001; 67: 213.
  • 4 van ’t Veer C, Golden NJ, Mann KG. Inhibition of thrombin generation by the zymogen facto VII: implications for the treatment of hemophilia A by factor VIIa. Blood 2000; 95: 1330-5.
  • 5 Monroe DM, Hoffman M, Oliver JA, Roberts HR. A possible mechanism of activated factor VII independent of tissue factor. Blood Coag Fibrinol 1998; 09 Suppl: (Suppl. 01) S15-S20.
  • 6 Key NS, Christie B, Henderson N, Nelsestuen GL. Possible therapeutic synergy between recombinant factor VIIa (rFVIIa) and prothrombin complex concentrate (PCC) in the treatment of hemophilia with inhibitors: evaluation of an in vitro test. Blood 2001; 96: 519a.